Lupus nephritis: treatment with mycophenolate mofetil

Kapitsinou, PP; Boletis, JN; Skopouli, FN; Boki, KA; Moutsopoulos, HM

dc.contributor.author	Kapitsinou, PP	en
dc.contributor.author	Boletis, JN	en
dc.contributor.author	Skopouli, FN	en
dc.contributor.author	Boki, KA	en
dc.contributor.author	Moutsopoulos, HM	en
dc.date.accessioned	2014-03-01T01:53:58Z
dc.date.available	2014-03-01T01:53:58Z
dc.date.issued	2004	en
dc.identifier.issn	1462-0324	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/27157
dc.subject	mycophenolate mofetil	en
dc.subject	lupus nephritis	en
dc.subject	proliferative nephritis	en
dc.subject	lupus membranous nephropathy	en
dc.subject	immunosuppression	en
dc.subject.classification	Rheumatology	en
dc.subject.other	MEMBRANOUS NEPHROPATHY	en
dc.subject.other	LONG-TERM	en
dc.subject.other	INTRAVENOUS CYCLOPHOSPHAMIDE	en
dc.subject.other	ERYTHEMATOSUS	en
dc.subject.other	GLOMERULONEPHRITIS	en
dc.subject.other	EFFICACY	en
dc.subject.other	DISEASE	en
dc.title	Lupus nephritis: treatment with mycophenolate mofetil	en
heal.type	journalArticle	en
heal.language	English	en
heal.publicationDate	2004	en
heal.abstract	Objective. To evaluate the safety and efficacy of mycophenolate mofetil (MMF) treatment in patients with lupus nephritis. Methods. Eighteen patients with biopsy-proven lupus nephritis (17 females, one male; mean age 31.6 yr; mean lupus duration 92 months; mean duration of nephritis 57 months; nine with focal proliferative glomerulonephritis, three with diffuse proliferative glomerulonephritis, six with membranous nephropathy) were included. With five exceptions, all patients had been treated previously with cyclophosphamide and were selected because of either toxicity or inadequate clinical response to treatment. MMF was given at 2 g daily in combination with steroids for up to 31months (mean 15.3 months). The side-effects of MMF were recorded and efficacy was assessed as the renal function profile. Results. Complete remission was observed in 10/18 patients and another 4/18 went into partial remission. Both creatinine clearance and proteinuria were significantly improved during MMF treatment in patients with the proliferative forms of nephritis. MMF demonstrated a steroid-sparing effect in the whole population. Treatment failure was recorded in 4/18 patients, all with membranous nephropathy. Two patients developed gastrointestinal complaints and infectious meningitis occurred in one patient. Conclusion. MMF appears to be an efficacious and safe treatment in patients with proliferative forms of lupus nephritis who do not respond to or cannot tolerate conventional treatment. The efficacy of MMF in lupus membranous nephropathy remains unclear.	en
heal.publisher	OXFORD UNIV PRESS	en
heal.journalName	RHEUMATOLOGY	en
dc.identifier.isi	ISI:000188990800021	en
dc.identifier.volume	43	en
dc.identifier.issue	3	en
dc.identifier.spage	377	en
dc.identifier.epage	380	en